Psychedelic Medicine


Starting a Psychedelic Medicine Practice

Log in To Watch the Recording

*Exclusive for members.

Thursday, October 26th at 5 pm Pacific, 8 pm Eastern >> Log in to Watch the Recording >>

An EXCLUSIVE Panel Discussion For Members Of The Psychedelic Medicine Association:

Starting a Psychedelic Medicine Practice

Panel Moderator:

Lynn Marie Morski, MD, JD

President - Psychedelic Medicine Association


L. Alison McInnes, MD, MS

L. Alison McInnes, MD, MS

Vice President of Scientific Affairs, Osmind

Dr. Alison McInnes, VP of Scientific Affairs at Osmind, is a nationally recognized expert in psychiatry and mood disorders, specializing in refractory diseases for over a decade. She's also an expert in ketamine treatment and psychedelic medicine. Dr. McInnes founded and served as the Medical Director for Kaiser Permanente's ketamine therapy program and was previously an Associate Professor of Psychiatry at Mount Sinai School of Medicine. She frequently speaks at national and international conferences, consults for cutting-edge biopharmaceutical companies in neuropsychiatry, and is a member of key professional associations. Her current clinical focus is on treatment-resistant mood disorders and complex cases.

Leslie Nylund, CPCU

Founder, TheraCover Psychedelic Insurance

Leslie has been an insurance professional for over 35 years bringing years of insurance experience in high level roles. Leslie currently has been with AHT Insurance for over four years to build and grow the New York region into a full-service brokerage operation with P&L responsibility. AHT was acquired in Dec. 2021 by Baldwin Risk Partners. Leslie was promoted 1/1/23 to National ManagingDirector in charge of Strategic Growth Initiatives while also maintaining her responsibility of overseeing the NY operations. In addition, she also leads the National Programs division responsible for rolling out new MGA programs; Direct to Consumer, traditional wholesale programs and Affinity and Associations programs capitalizing on the many existing corporate relationships. She is the Founder of the new TheraCover Professional Liability/Medical malpractice insurance program, covering medical professionals, clinicians, therapists etc. involved in Psychedelic assisted therapy. Prior to her tenure with AHT Insurance/Baldwin Risk Partners, Leslie was the Chief Operating Officer and Director of Strategy at Innovative Coverage Concepts (ICC), a large MGA, where she built and implemented strategies to drive operational efficiencies through digitalization–outsourcing and re-alignment resulting in an increase in EBITDA. Leslie was President and COO of SterlingRisk, a national broker based in Woodbury, NY as well as a National Partner and later Chief Placement Office at Willis North America. Leslie has also held various senior leadership positions at Marsh and Guy Carpenter.

David Esselman

David Esselman

Executive Director, BrainFutures

David Esselman is the Executive Director of BrainFutures, where he has shaped the organization’s research and public education agendas since March 2022. He is sought out as a leading voice in the emerging field of medical psychedelics and has presented at multiple conferences on the promise of psychedelic-assisted therapy and the vital importance of ensuring that these groundbreaking new treatments are available to all who may benefit. Esselman’s prior experience in the psychedelic-assisted therapy field includes consulting on the development of a certification standard for psychedelic-assisted therapists and advising government regulators in several U.S. states, the federal government, and Europe on access-focused regulation for psychedelic-assisted therapy treatment models.

While the Psychedelic Medicine Association’s main mission is to educate providers on how to discuss psychedelic medicine with your patients and know when and how to refer to psychedelic practitioners, it turns out that once clinicians learn about psychedelic medicine, they often choose to become a psychedelic practitioner themselves – so we’d like to help those clinicians get off on the right foot! 

We previously did a webinar featuring some of the psychedelic training programs, and we plan to do more in the future (as there are SO many programs to choose from). This month, however, we’re going to get into some of the logistical issues you’ll need to cover when starting a psychedelic medicine practice.

From the new CPT codes for psychedelic therapy, to how to get malpractice insurance to what type of EMR to choose, there are a number of issues that are specific to practices involving psychedelic medicine and therapies.

This month we are truly fortunate to have panelists who have spent an immense amount of time focused on what psychedelic practices need. They discussed the following:

  • What kinds of malpractice psychedelic practitioners will need 
  • What type of EMR qualities best suit a psychedelic practice
  • What kind of codes practitioners will need to use for billing

…and much more!

This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here.

You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.